TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04102943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus tablet
Description: * Orally, twice a day in the morning and night~* After first dose 0.1mg/kg, check the blood concentration of tacrolimus at each visit and adjust the dose to acheive the blood concentration maintaining at 7\~12ng/ml for 0 to 3months and then at 5\~8ng/ml for 3 to 6months of study treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus capsules
Description: * Orally, twice a day in the morning and night~* After first dose 0.1mg/kg, check the blood concentration of tacrolimus at each visit and adjust the dose to acheive the blood concentration maintaining at 7\~12ng/ml for 0 to 3months and then at 5\~8ng/ml for 3 to 6months of study treatment.
Study: NCT03584100

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tourniquet 8000
Description: Pneumatic tourniquet with appropriate upper extremity cuff, pressure sensing, and ability to set device at 40 mmHg of pressure

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tourniquet 8000
Description: Pneumatic tourniquet with appropriate upper extremity cuff, pressure sensing, and ability to set device at 40 mmHg of pressure
Study: NCT02059902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Lidocaine infusion runs for a total of 24 hours

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline runs for a total of 24 hours
Study: NCT02422472

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound guided peripheral IV placement
Description: Accucath™ 20 Gax 5.7cm catheter
Study: NCT03273543

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane® Defyne
Description: hyaluronic acid filler injection

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane® Defyne
Description: hyaluronic acid filler injection
Study: NCT03459261

Intervention type: DIAGNOSTIC_TEST
Intervention: blood sample on admission (ADD), first postoperative day (POD1) and fourth postoperative day (POD4)
Description: Laboratory analyses of peripheral venous blood on admission (blood sample ADD), 24 hours after surgery (blood sample POD1) and fourth-day after surgery (blood sample POD4) included biochemical analysis, complete blood count, C-reactive protein (CPR), procalcitonin (PCT), albumin/protein level, prothrombin time and international normalized ratio (INR) (only on admission) and for determination of cytokines: tumor necrosis factor alpha (TFN-α), interleukin-6 (IL-6), interleukin-10 (IL-10).
Study: NCT03343379

Intervention type: OTHER
Group type: OTHER
Intervention: Core stability tests
Description: A test battery comprised of field tests to evaluate core stability
Study: NCT03137914

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous chondrocyte transplantation
Description: intraarticular injection into the TMJ (arthrocentesis) of autologous chondrocytes diluted in hyaluronic acid

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: orthognathic surgery
Description: Orthognathic surgery for correction of dentofacial deformity, performed before the cellular transplantation
Study: NCT00535067

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaires taking 60 minutes total to complete.
Study: NCT01064843

Intervention type: DEVICE
Intervention: Imtec MDI
Description: 4 Imtec MDI
Study: NCT02111343

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer-based auditory training (CBAT)
Description: There are 3 listening games (i.e. Doggy, Who-Is-Right, Story-in-noise) that target on speech-in-noise training and 1 listening game (i.e. TATP) that aims to train dichotic listening.~Patient was required to undergo the training for 30 minutes per day, 5 sessions per week, for a duration of 12 weeks. Parents were advised to keep a journal to record child's training hour of the day.
Study: NCT01874977

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pedometer
Description: Will receive the educational booklet and discussion, plus a pedometer and a diary to record their daily step counts from the pedometer.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Educational materials
Description: Will receive the educational booklet (Be Active Your Way: A guide for Adults; http://www.health.gov/paguidelines/adultguide/default.aspx).and a discussion of simple ways to increase physical activity in daily life based on the booklet, following the baseline assessment.
Study: NCT01106703

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PG102, a water soluble extract from Actinidia arguta
Description: PG102 two tables(Actinidia arguta extract:Microcrystalline cellulose(1:1)mixed powder 1120mg) twice a day for 8weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo two tables(equivalent dose of Microcrystalline cellulose) twice a day for 8weeks
Study: NCT02174211

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Intravitreal injection of ranibizumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Intravitreal injection of ranibizumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: Intravitreal injection of aflibercept
Study: NCT04131829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine - immediate treatment
Description: Following the Baseline assessment, OCD subjects will be randomized to receive either immediate fluoxetine monotherapy or delayed fluoxetine, after a 6-week placebo lead-in.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine - delayed treatment
Description: Following the Baseline assessment, OCD subjects will be randomized to receive either immediate fluoxetine monotherapy or delayed fluoxetine, after a 6-week placebo lead-in.
Study: NCT01874977

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational materials
Description: Will receive the educational booklet (Be Active Your Way: A guide for Adults; http://www.health.gov/paguidelines/adultguide/default.aspx).and a discussion of simple ways to increase physical activity in daily life based on the booklet, following the baseline assessment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational materials
Description: Will receive the educational booklet (Be Active Your Way: A guide for Adults; http://www.health.gov/paguidelines/adultguide/default.aspx).and a discussion of simple ways to increase physical activity in daily life based on the booklet, following the baseline assessment.
Study: NCT03367364

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient education bundle (PEB),
Description: A charge nurse will intervene in real-time via an EHR-triggered alert when there is documentation that a dose of VTE prophylaxis medication is not given for any reason. The charge nurse will speak to the bedside nurse and one of them will provide the patient with the education bundle including one-on-one personalized discussion, supplemented by a 2-page paper handout and patient education video.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Nurse feedback and coaching (NFC)
Description: Nurse leadership (i.e. managers, directors) will provide data to all nurses on their personal clinical effectiveness with the proportion of doses of VTE prophylaxis administered. The data will have comparisons to their nurse peers on the same floor. Coaching for nurses will include one-on-one conversations with bedside nurses with lower performance than their peers.
Study: NCT00515086

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: Tablets taken once a day with a full glass of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Tablets taken once a day with a full glass of water.
Study: NCT01874977

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Step count goals
Description: Will receive the educational booklet and discussion, and the pedometer and step diary, plus will be given individualized daily step targets.
Study: NCT03743259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LuminoMark inj. 0.1mL
Description: Injection LuminoMark inj. (Conc. for fluorescence) 0.1mL once in this study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LuminoMark inj. 0.2mL
Description: Injection LuminoMark inj. (Conc. for fluorescence) 0.2mL once in this study.
Study: NCT00515086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Tablets taken once a day with a full glass of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Tablets taken once a day with a full glass of water.
Study: NCT03743259

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Charcotrace Inj.
Description: Injection Charcotrace Inj. about 0.3\~1mL once in this study.
Study: NCT00515086

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Salvage surgical resection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Salvage surgical resection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Salvage surgical resection
Study: NCT03824561

Intervention type: DRUG
Intervention: Vedolizumab
Description: Vedolizumab IV infusion
Study: NCT04336332

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Sulfate + Azithromycin
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Sulfate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Sulfate
Description: Given PO
Study: NCT02677662

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diesel Exhaust
Description: Dilute diesel exhaust

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Filtered air
Description: Filtered air
Study: NCT02828280

Intervention type: DEVICE
Intervention: NuMask
Description: The NuMask is a relatively new mask ventilation device that has been registered with the FDA and used in the United States since 2006.

Intervention type: DEVICE
Intervention: NuMask
Description: The NuMask is a relatively new mask ventilation device that has been registered with the FDA and used in the United States since 2006.
Study: NCT03418402

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Airseal®
Description: Total laparoscopic hysterectomy: Approach according to the Open-Laparoscopy technique and use of the insufflation system.
Study: NCT02828280

Intervention type: DEVICE
Intervention: Traditional mask
Description: A traditional air inflated facemark used to ventilate patients

Intervention type: DEVICE
Intervention: Traditional mask
Description: A traditional air inflated facemark used to ventilate patients
Study: NCT03446599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxocobalamin
Description: One intravenous dose of 5mg hydroxocobalamin, which is the current FDA-approved adult dose for carbon monoxide poisoning, reconstituted in 200ml normal saline will be administered over 10-15minutes at the time of initiation of cardiopulmonary bypass.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylene Blue
Description: One intravenous dose of methylene blue 2mg/kg, which has been the accepted dose for vasoplegia, diluted in 200ml normal saline will be administered over 10-15minutes at the time of initiation of cardiopulmonary bypass.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 200ml normal saline will be administered intravenously over 10-15minutes at the time of initiation of cardiopulmonary bypass.
Study: NCT02304822

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Multiple-dose of Ciprofloxacin prophylaxis
Description: Multiple-dose prophylactic antibiotic of 200mg intravenous ciprofloxacin, 30 minutes before surgery and within 12 hours after surgery additionally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single-dose of Ciprofloxacin prophylaxis
Description: Single-dose prophylactic antibiotic of 200mg intravenous ciprofloxacin, 30 minutes before surgery only.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zero-dose of Ciprofloxacin prophylaxis
Description: Zero-dose of ciprofloxacin prophylaxis with none intravenous ciprofloxacin either preoperatively or postoperatively
Study: NCT04489784

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infrared Laser
Description: An aluminum gallium arsenide (AlGaAs) diode laser device (Twin laser, MMOptics, São Carlos, SP, Brazil) was used. The irradiation parameters were as follows: infrared laser (808 nm wavelength) with a spot area of 0.04 cm2, and an average optical power of 100 mW operated in a continuous mode during 1 minute per point, leading to an irradiance of 2,500 mW/cm2, energy of 6 J and fluence of 125 J/cm2 per point. The laser was applied on ballerina's feet twice a week during three months.
Study: NCT03201757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 3831
Description: Olanzapine + samidorphan, daily oral dosing
Study: NCT03418402

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard insufflator
Description: Standard insufflator
Study: NCT01463072

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03633786

Intervention type: PROCEDURE
Group type: OTHER
Intervention: standard laparoscopic surgery
Description: removal of endometriotic lesions with laparoscopic instruments (KARL STORZ Gesellschaft mit beschränkter Haftung \& Co., Tuttlingen, Germany) using 4 transperitoneal abdominal accesses and trocars from 5 to 12 mm

Intervention type: PROCEDURE
Group type: OTHER
Intervention: robot-assisted surgery
Description: removal of endometriotic lesions with da Vinci Xi robotic system (Intuitive Surgical Inc., Sunnyvale, CA, USA), using 5 transperitoneal abdominal accesses and trocars from 8 and 12 mm.~The robotic mechanical arms are associated with the 8 mm abdominal trocars to allow intervention by the first operator, with the aid of a surgical console.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: assessment of sexual function
Description: assessment of sexual function using a validate questionnaire (Female Sexual Function Index (FSFI)), before and 3 months after surgery

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: assessment of sexual function
Description: assessment of sexual function using a validate questionnaire (Female Sexual Function Index (FSFI)), before and 3 months after surgery

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: assessment of bowel symptoms
Description: assessment of bowel symptoms using a validated questionnaire (Knowles-Eccersley-Scott-Symptom Questionnaire (KESS)), before and 3 months after surgery

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: assessment of bowel symptoms
Description: assessment of bowel symptoms using a validated questionnaire (Knowles-Eccersley-Scott-Symptom Questionnaire (KESS)), before and 3 months after surgery

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: assessment of urinary symptoms
Description: assessment of urinary symptoms using a validated questionnaire (Bristol Female Lower Urinary Tract Symptoms (BFLUTS)), before and 3 months after surgery

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: assessment of urinary symptoms
Description: assessment of urinary symptoms using a validated questionnaire (Bristol Female Lower Urinary Tract Symptoms (BFLUTS)), before and 3 months after surgery
Study: NCT02857855

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 80% fraction of inspired oxygen for 6 postoperative hours
Description: 80% fraction of inspired oxygen delivered for 6 postoperative hours, either by a nonrebreathing facemask with a reservoir or by a respirator
Study: NCT03278158

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects in the placebo arm will receive a single oral tablet containing no active drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XEN-D0501, 1 mg/tablet
Description: Subjects in this arm will receive a single oral tablet of XEN-D0501, 1 mg/tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XEN-D0501, 2 mg/tablet
Description: Subjects in this arm will receive a single oral tablet of XEN-D0501, 2 mg/tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XEN-D0501, 4 mg/tablet
Description: Subjects in this arm will receive a single oral tablet of XEN-D0501, 4 mg/tablet
Study: NCT02857855

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 28% fraction of inspired oxygen for 6 postoperative hours
Description: 28% fraction of inspired oxygen delivered for 6 postoperative hours, either by a Venturi facemask or by a respirator
Study: NCT03285217

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ensure Plus Advance
Description: Supplements, labeled only with the name of the participant and his/her identification number, will be provided to the participants in the Translational Research Unit of the Miguel Servet Hospital. Every 2 weeks, changes in body composition, in particular in fat and muscle, will be assessed by bioelectrical impedance analysis (BIA). Likewise they will be asked about compliance and their diets will be controlled by a nutritionist. Fresh stool samples, urine and blood will be collected pre- and post treatment. An extensive bloodwork will be performed at the Clinical Biochemistry Service at the Miguel Servet Hospital (plasma HMB, total cholesterol, triglycerides, LDL\&HDL-cholesterol, free fatty acids, glucose, insulin, β-hydroxybutyrate, hs-CRP, and liver transaminases (AST, ALT, GGT).
Study: NCT03043066

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Scaling and root planing
Description: subjects underwent full mouth supragingival and subgingival scaling

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: scaling and root planing along with antibiotic intervention
Description: subjects underwent full mouth supragingival and subgingival scaling along with antibiotic intervention of amoxicillin of 500 mg and metronidazole of 400 mg thrice daily for 7 days
Study: NCT03985254

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strength Training Group (STG)
Description: The strength training program will consist of applying resistance and progressive exercises for strength gain and will be based on the training principles recommended by the American College of Sport Medicine. The exercises were chosen based on a pilot study that successfully applied the protocol to 10 participants with FPD (data to be published) and other strength training studies (MASCALL et al, 2003; DISTEFANO et al, 2009; REIMAN et al, 2012; BALDON et al, 2014; SILVA et al, 2015).~Initially, the goal will be the development of neuromotor control and resistance (load \<50% of the one repetition maximum test \[1RM\]), and in subsequent weeks the goal will be the development of muscle strength (load\> 70% 1RM). In addition, the protocol will initially focus on strengthening the hip and trunk muscles and after four weeks of training, exercises for the knee muscles will be included.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength and Power Training Group (SPTG)
Description: Participants who are allocated to this group will perform the same exercise program performed by the STG, but with the addition of exercises that emphasize power gain. As in the other group, initially, the objective will be the development of neuromotor control and resistance (load \<50% of the one repetition maximum test \[1RM\]). However, in subsequent weeks the goal will be to develop strength (load\> 70% 1RM) and muscle power (load between 40-60% 1RM).
Study: NCT03285217

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ensure High Protein
Description: Supplements, labeled only with the name of the participant and his/her identification number, will be provided to the participants in the Translational Research Unit of the Miguel Servet Hospital. Every 2 weeks, changes in body composition, in particular in fat and muscle, will be assessed by bioelectrical impedance analysis (BIA). Likewise they will be asked about compliance and their diets will be controlled by a nutritionist. Fresh stool samples, urine and blood will be collected pre- and post treatment. An extensive bloodwork will be performed at the Clinical Biochemistry Service at the Miguel Servet Hospital (plasma HMB, total cholesterol, triglycerides, LDL\&HDL-cholesterol, free fatty acids, glucose, insulin, β-hydroxybutyrate, hs-CRP, and liver transaminases (AST, ALT, GGT).
Study: NCT01596959

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation utilising the ECI contact software
Description: irrigated radiofrequency ablation to the right atrium using the ECI contact data
Study: NCT01031706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypertonic Saline
Description: inhaled HS (6% NaCl, 4mL) three times a day for 28 days
Study: NCT01596959

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Radiofrequency ablation without the use of ECI contact data
Description: irrigated RF ablation without the use of ECI contact data
Study: NCT03587038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OKN 007
Description: 400 mg OKN-007/mL in a phosphate buffer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OKN 007
Description: 400 mg OKN-007/mL in a phosphate buffer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 75 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 75 mg/m2

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Photon/Proton IMRT
Description: standard of care treatment to be given 1 to 2 hours after OKN-007

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Photon/Proton IMRT
Description: standard of care treatment to be given 1 to 2 hours after OKN-007
Study: NCT05967442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: Magnesium Sulfate 2gm in 50ml D5W over 20 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide 10mg
Description: Metoclopramide 10mg in 50ml D5W over 20 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prochlorperazine (Compazine) Injection
Description: Prochlorperazine 10mg in 50ml D5W over 20 minutes
Study: NCT03514589

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nasal Tetracosactide
Description: Bioavailability of nasal synacthen compared to IV comparator